Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ziprasidone (Geodon) Clear all
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

NCT03557931
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 27, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

Maternal And Infant Antipsychotic Study

NCT06049953
View directory record Official record
Conditions
Antipsychotics, Pregnancy
Interventions
Antipsychotics, Non-antipsychotic medication, No Medication
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated No phase listed Observational

Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

NCT01598324
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Geodon (Ziprasidone) for Posttraumatic Stress Disorder

NCT00208208
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Post-Traumatic Stress Disorder, PTSD
Interventions
Ziprasidone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2006 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Geodon for the Treatment of Refractory Social Anxiety Disorder

NCT00215150
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Ziprasidone, Sertraline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

NCT01231074
View directory record Official record
Conditions
Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions
Metformin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

NCT00338949
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome X, Insulin Resistance
Interventions
Switch, Control
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional Results available

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

NCT00257192
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, Ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
46
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Not listed Phase 4 Interventional

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

NCT02282085
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Drug
Lead sponsor
Matt Byerly
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

NCT00237666
View directory record Official record
Conditions
Bipolar II Disorder, Major Depressive Episode
Interventions
Ziprasidone
Drug
Lead sponsor
The Medical Research Network
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
New York, New York • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 27, 2026, 5:30 AM EDT
Terminated Phase 4 Interventional Results available

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

NCT01844700
View directory record Official record
Conditions
High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
Interventions
Ziprasidone, aripiprazole, quetiapine, or risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
13 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

NCT00254202
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone, Ziprasidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
33
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

NCT00555997
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Los Angeles, California • Farmington, Connecticut • Norwich, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

NCT00483548
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
60
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

NCT01211522
View directory record Official record
Conditions
Delirium, Impaired Cognition, Long Term Psychologic Disorders
Interventions
Haloperidol, Ziprasidone, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone in Pediatric Bipolar Disorder

NCT00622739
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Geodon in Weight Loss Study for Bipolar Disorders

NCT00472641
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ziprasidone/Geodon
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression

NCT00141271
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Geodon (Ziprasidone), Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
72
States / cities
Birmingham, Alabama • Dana Point, California • La Mesa, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

NCT01006551
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
4
States / cities
Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pfizer/IVGTT/Ziprasidone/Olanzapine

NCT00205725
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 27, 2026, 5:30 AM EDT
Not listed No phase listed Observational

DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

NCT00752960
View directory record Official record
Conditions
Psychoses
Interventions
Not listed
Lead sponsor
Genomas, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Hartford, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Sep 27, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 27, 2026, 5:30 AM EDT